A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3667 Once Daily for 24 Weeks in Adult Subjects with Dermatomyositis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GLPG 3667 (Primary)
Indications Dermatomyositis
Focus Therapeutic Use
Acronyms GALARISSO
Sponsors Galapagos NV

Most Recent Events

14 Feb 2025 Planned End Date changed from 1 Mar 2025 to 1 Jun 2026.
14 Feb 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Jan 2026.
23 May 2023 According to a Galapagos media release, first patient was dosed .

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight